{"id":204780,"date":"2026-08-25T11:44:26","date_gmt":"2026-08-25T14:44:26","guid":{"rendered":"https:\/\/goias.gov.br\/escoladesaude\/?page_id=204780"},"modified":"2026-08-25T12:21:38","modified_gmt":"2026-08-25T15:21:38","slug":"pcdts-e-recome","status":"publish","type":"page","link":"https:\/\/goias.gov.br\/escoladesaude\/pcdts-e-recome\/","title":{"rendered":"PROTOCOLOS CL\u00cdNICOS (PCDT’s) E RELA\u00c7\u00c3O ESTADUAL COMPLEMENTAR DE MEDICAMENTOS (RECOME)"},"content":{"rendered":"\t\t
\n\t\t\t\t
\n \t\t
\n\t\t\t\t\t\t\t\t\t

Essa \u00e9 a lista de medicamentos e produtos de Cannabis que constam na RECOME e seus respectivos Protocolos Cl\u00ednicos e Diretrizes Terap\u00eauticas (PCDT’s):<\/span>\u00a0<\/span><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\n<\/div>\n

\n \t\t
\n\t\t\t\t\t\t\t\t\t
ORDEM<\/strong><\/td>DENOMINA\u00c7\u00c3O<\/strong><\/td>USOS APROVADOS E SEUS RESPECTIVOS PROTOCOLOS CL\u00cdNICOS ESTADUAIS<\/strong><\/td>PORTARIAS<\/strong><\/td><\/tr>
01<\/strong><\/td>Aflibercepte<\/td>Edema macular secund\u00e1rio \u00e0 retinopatia diab\u00e9tica
<\/a>Edema macular secund\u00e1rio \u00e0 oclus\u00e3o venosa da retina
<\/a>Degenera\u00e7\u00e3o macular relacionada \u00e0 idade forma neovascular<\/a><\/td>		Portaria 03\/2019-GAB\/SES-GO<\/a>
(ver DOE-GO, de 17\/06\/2019 – Ed. 23575 – P\u00e1g. 18)<\/span><\/td><\/tr>
02<\/strong><\/td>Belimumabe<\/td>Nefrite l\u00fapica<\/a><\/td>Portaria 2.804\/2023-SES-GO<\/a>
(ver DOE-GO, de 25\/01\/2024 – Ed. 24.211 – P\u00e1g. 80)<\/span><\/td><\/tr>
03<\/strong><\/td>Brometo de Umeclid\u00ednio<\/td>Doen\u00e7a pulmonar obstrutiva cr\u00f4nica (DPOC) grave a muito grave<\/a><\/td>Portaria 2.188\/2024-SES-GO<\/a>
(ver DOE-GO, de 29\/07\/2024 – Ed. 24.337 – P\u00e1g. 62)<\/span><\/td><\/tr>
04<\/strong><\/td>Canabidiol<\/td>Epilepsias F\u00e1rmaco-Resistentes grave<\/a><\/td>Portaria 2.887\/2025-SES-GO<\/a>
(ver DOE-GO, de 13\/10\/2025 – Ed. 24.639 – P\u00e1g. 33)<\/span><\/td><\/tr>
05<\/strong><\/td>Clobetasol, Propionato de<\/td>Dermatite at\u00f3pica moderada a grave<\/a><\/td>Portaria 2.188\/2024-SES-GO<\/a>
(ver DOE-GO, de 29\/07\/2024 – Ed. 24.337 – P\u00e1g. 62)<\/span><\/td><\/tr>
06<\/strong><\/td>Cloridrato de valganciclovir<\/td>Profilaxia da doen\u00e7a por citomegalov\u00edrus(CMV) em pacientes de alto risco que submeteram a transplante renal com sorologia discordante (D+\/R-) ou em pacientes de transplante renal que foram\/est\u00e3o submetidos a tratamento medicamentoso com anticorpos anti-linfocit\u00e1rios depletores (GAT)<\/a><\/td>Portaria 283\/2016-GAB-SES-GO<\/a>
(ver DOE-GO, de 18\/03\/2016 – Ed. 22.288 – P\u00e1g. 22)<\/span><\/td><\/tr>
07<\/strong><\/td>Denosumabe<\/td>Osteoporose<\/a><\/td>Portaria 2.188\/2024-SES-GO<\/a>
(ver DOE-GO, de 29\/07\/2024 – Ed. 24.337 – P\u00e1g. 62)<\/span><\/td><\/tr>
08<\/strong><\/td>Dipropionato de beclometasona + formoterol + glicopirr\u00f4nio (Trimbow<\/em>\u00ae)<\/td>Doen\u00e7a pulmonar obstrutiva cr\u00f4nica (DPOC) grave a muito grave<\/a><\/td>Portaria 2.188\/2024-SES-GO<\/a>
(ver DOE-GO, de 29\/07\/2024 – Ed. 24.337 – P\u00e1g. 62)<\/span><\/td><\/tr>
09<\/strong><\/td>Dupilumabe<\/td>Dermatite at\u00f3pica moderada a grave<\/a><\/td>Portaria 2.188\/2024-SES-GO<\/a>
(ver DOE-GO, de 29\/07\/2024 – Ed. 24.337 – P\u00e1g. 62)<\/span><\/td><\/tr>
10<\/strong><\/td>Furoato de fluticasona + umeclidinio + vilanterol (Trelegy<\/em>\u00ae)<\/td>Doen\u00e7a pulmonar obstrutiva cr\u00f4nica (DPOC) grave a muito grave<\/a><\/td>Portaria 2.188\/2024-SES-GO<\/a>
(ver DOE-GO, de 29\/07\/2024 – Ed. 24.337 – P\u00e1g. 62)<\/span><\/td><\/tr>
11<\/strong><\/td>Implante Biodegrad\u00e1vel de Dexametasona<\/td>Edema macular secund\u00e1rio \u00e0 retinopatia diab\u00e9tica
<\/a>Edema macular secund\u00e1rio \u00e0 oclus\u00e3o venosa da retina<\/a><\/td>		Portaria 03\/2019-GAB\/SES-GO<\/a>
(ver DOE-GO, de 17\/06\/2019 – Ed. 23575 – P\u00e1g. 18)<\/span><\/td><\/tr>
12<\/strong><\/td>Nintedanibe<\/td>Fibrose pulmonar idiop\u00e1tica<\/a><\/td>P<\/a>ortaria 2.854\/2022-SES-GO<\/a>
<\/a>(ver DOE-GO, de 07\/12\/2022 – Ed. 23.934 – P\u00e1g. 35)<\/span><\/td><\/tr>
13<\/strong><\/td>Palmitato de Paliperidona<\/td>Esquizofrenia<\/a><\/td>Portaria 2.118\/2022-SES-GO<\/a>
(ver DOE-GO, de 20\/07\/2022 – Ed. 23.841 – P\u00e1g. 6)<\/span><\/td><\/tr>
14<\/strong><\/td>Pirfenidona<\/td>Fibrose pulmonar idiop\u00e1tica<\/a><\/td>Portaria 2.854\/2022-SES-GO<\/a>
(ver DOE-GO, de 07\/12\/2022 – Ed. 23.934 – P\u00e1g. 35)<\/span><\/td><\/tr>
15<\/strong><\/td>Ranibizumabe<\/td>Edema macular secund\u00e1rio \u00e0 retinopatia diab\u00e9tica
<\/a>Edema macular secund\u00e1rio \u00e0 oclus\u00e3o venosa da retina
<\/a>Degenera\u00e7\u00e3o macular relacionada \u00e0 idade forma neovascular<\/a><\/td>		Portaria 03\/2019-GAB\/SES-G
<\/a>(ver DOE-GO, de 17\/06\/2019 – Ed. 23575 – P\u00e1g. 18<\/span><\/td><\/tr>
16<\/strong><\/td>Riociguate<\/td>Hipertens\u00e3o pulmonar Tromboemb\u00f3lica Cr\u00f4nica<\/a><\/td>Portaria 2.102\/2021-SES-GO<\/a>
(ver DOE-GO, de 02\/12\/2021 – Ed. 23.688 – P\u00e1g. 10)<\/span><\/td><\/tr>
17<\/strong><\/td>Semaglutida<\/td>Sobrepeso (IMC \u2265 27 kg\/m2<\/sup>) e obesidade em crian\u00e7as e adolescentes<\/a><\/td>P<\/a>ortaria 016\/2026-SES-GO<\/a>
<\/a>(ver DOE-GO, de\u00a019\/03\/2026 – Ed.\u00a024.742 – P\u00e1g. 14)<\/span><\/td><\/tr>
18<\/strong><\/td>Somatropina<\/td>Transtorno do crescimento em crian\u00e7a nascida pequena para idade gestacional (PIG)<\/a><\/td>Portaria 2.112\/2022-SES-GO<\/a>
(ver DOE-GO, de 19\/07\/2022 – Ed. 23.840 – P\u00e1g. 14)<\/span><\/td><\/tr>
19<\/strong><\/td>Teriparatida<\/td>Osteoporose<\/a><\/td>Portaria 2.188\/2024-SES-GO<\/a>
(ver DOE-GO, de 29\/07\/2024 – Ed. 24.337 – P\u00e1g. 62)<\/span><\/td><\/tr>
20<\/strong><\/td>Xinafoato de salmeterol + propionato de fluticasona<\/td>Doen\u00e7a pulmonar obstrutiva cr\u00f4nica (DPOC) grave a muito grave<\/a><\/td>Portaria 285\/2018-SES-GO<\/a>
(ver DOE-GO, de 02\/01\/2014 – Ed. 21.743 – P\u00e1g. 14)
<\/span>Portaria 2.188\/2024-SES-GO<\/a>
(ver DOE-GO, de 29\/07\/2024 – Ed. 24.337 – P\u00e1g. 62)<\/span><\/td><\/tr><\/tbody><\/table>\t\t\t\t\t\t\t\t<\/div>\n\t\t\n<\/div>\n
\n \t\t
\n\t\t\t\t\t\t\t\t\t

Lista de medicamentos avaliados pela Comiss\u00e3o Estadual de Incorpora\u00e7\u00e3o de Tecnologias em Sa\u00fade (CEITS) ou pela comiss\u00e3o antecessora denominada Comiss\u00e3o Estadual de Farm\u00e1cia e Terap\u00eautica (CEFT), que n\u00e3o foram incorporados \u00e0 RECOME ou que foram desincorporados da RECOME e suas respectivas portarias:<\/span><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\n<\/div>\n

\n \t\t
\n\t\t\t\t\t\t\t\t\t
ORDEM<\/strong><\/td>MEDICAMENTO<\/strong><\/td>STATUS<\/strong><\/td>PORTARIA<\/strong><\/td><\/tr>
01<\/strong><\/td>\u00c1cido Zoledr\u00f4nico para tratamento de Osteoporose<\/td>Decis\u00e3o de desincorpora\u00e7\u00e3o<\/td>Portaria 2.188\/2024-SES-GO<\/a>
(ver DOE-GO, de 29\/07\/2024 – Ed. 24.337 – P\u00e1g. 62)<\/td><\/tr>
02<\/strong><\/td>Aripiprazol para tratamento de esquizofrenia<\/td>Decis\u00e3o de desincorpora\u00e7\u00e3o<\/td>Portaria 2.111\/2022-SES-GO<\/a>
(ver DOE-GO, de 19\/07\/2022 – Ed. 23.840 – P\u00e1g. 14)<\/td><\/tr>
03<\/strong><\/td>Ciclosporina para tratamento de dermatite at\u00f3pica<\/td>Decis\u00e3o de desincorpora\u00e7\u00e3o<\/td>Portaria 2.188\/2024-SES-GO<\/a>
(ver DOE-GO, de 29\/07\/2024 – Ed. 24.337 – P\u00e1g. 62)<\/td><\/tr>
04<\/strong><\/td>Vedolizumabe para tratamento de Doen\u00e7a de Crohn<\/td>Decis\u00e3o de n\u00e3o incorpora\u00e7\u00e3o<\/td>Portaria 1.723\/2024-SES-GO<\/a>
(ver DOE-GO, de 24\/06\/2024 – Ed. 24.318 – P\u00e1g. 16)<\/td><\/tr>
05<\/strong><\/td>Ustequinumabe para tratamento de Doen\u00e7a de Crohn<\/td>Decis\u00e3o de n\u00e3o incorpora\u00e7\u00e3o<\/td>Portaria 1.723\/2024-SES-GO<\/a>
(ver DOE-GO, de 24\/06\/2024 – Ed. 24.318 – P\u00e1g. 16)<\/td><\/tr>
06<\/strong><\/td>Ustequinumabe para tratamento de psor\u00edase<\/td>Decis\u00e3o de desincorpora\u00e7\u00e3o<\/td>Portaria 2.188\/2024-SES-GO<\/a>
(ver DOE-GO, de 29\/07\/2024 – Ed. 24.337 – P\u00e1g. 62)<\/td><\/tr>
07<\/strong><\/td>Selexipague para tratamento de hipertens\u00e3o arterial pulmonar<\/td>Decis\u00e3o de n\u00e3o incorpora\u00e7\u00e3o<\/td>Portaria 1.128\/2021-SES-GO<\/a>
(ver DOE-GO, de 14\/07\/2021 – Ed. 23.592 – P\u00e1g. 18)<\/td><\/tr>
08<\/strong><\/td>Malato de Sunitinibe para tratamento de carcinoma de c\u00e9lulas renais metast\u00e1tico ou avan\u00e7ado<\/td>Decis\u00e3o de n\u00e3o avalia\u00e7\u00e3o pela comiss\u00e3o por n\u00e3o atender regimento (solicita\u00e7\u00e3o para doen\u00e7a oncol\u00f3gica)<\/td>Portaria 172\/2021-SES-GO<\/a>
(ver DOE-GO, de 27\/01\/2021 – Ed. 23.477 – P\u00e1g. 6)<\/td><\/tr>
09<\/strong><\/td>Enzalutamida para tratamento de c\u00e2ncer de pr\u00f3stata resistente \u00e0 castra\u00e7\u00e3o mestast\u00e1tico com progress\u00e3o de doen\u00e7a p\u00f3s-quimioterapia<\/td>Decis\u00e3o de n\u00e3o avalia\u00e7\u00e3o pela comiss\u00e3o por n\u00e3o atender regimento (solicita\u00e7\u00e3o para doen\u00e7a oncol\u00f3gica)<\/td>Portaria 173\/2021-SES-GO<\/a>
(ver DOE-GO, de 27\/01\/2021 – Ed. 23.477 – P\u00e1g. 6)<\/td><\/tr>
10<\/strong><\/td>Brometo de Glicopirr\u00f4nio para tratamento de Doen\u00e7a Pulmonar Obstrutiva Cr\u00f4nica<\/td>Decis\u00e3o de desincorpora\u00e7\u00e3o<\/td>Portaria 173\/2021-SES-GO<\/a>
(ver DOE-GO, de 27\/01\/2021 – Ed. 23.477 – P\u00e1g. 6)<\/td><\/tr>
11<\/strong><\/td>Brometo de Tiotr\u00f3pio para tratamento de Doen\u00e7a Pulmonar Obstrutiva Cr\u00f4nica<\/td>Decis\u00e3o de desincorpora\u00e7\u00e3o<\/td>Portaria 2.188\/2024-SES-GO<\/a>
(ver DOE-GO, de 29\/07\/2024 – Ed. 24.337 – P\u00e1g. 62)<\/td><\/tr>
12<\/strong><\/td>Incorpora\u00e7\u00e3o de Insulina Recombinante An\u00e1loga \u00e0 Humana de A\u00e7\u00e3o Basal (Glargina, Detemir, Degludeca) para tratamento de Diabete Mellitus tipo I<\/td>Decis\u00e3o de n\u00e3o incorpora\u00e7\u00e3o<\/td>Portaria 314\/2017-GAB-SES-GO<\/a>
(ver DOE-GO, de 04\/05\/2017 – Ed. 22.560, P\u00e1g. 31)<\/td><\/tr>
13<\/strong><\/td>Incorpora\u00e7\u00e3o de Fampridina para tratamento da incapacidade de deambula\u00e7\u00e3o na Esclerose M\u00faltipla<\/td>Decis\u00e3o de n\u00e3o incorpora\u00e7\u00e3o<\/td>Portaria 575\/2018-GAB-SES-GO<\/a>
(ver DOE-GO, de 09\/10\/2018 – Ed. 22.182, P\u00e1g. 18)<\/td><\/tr>
14<\/strong><\/td>Incorpora\u00e7\u00e3o de Clobetasol spray e shampoo para tratamento da psor\u00edase<\/td>Decis\u00e3o de n\u00e3o incorpora\u00e7\u00e3o<\/td>Portaria 542\/2018-GAB-SES-GO<\/a>
(ver DOE-GO, de 22\/09\/2018 – Ed. 22.169, P\u00e1g. 18)<\/td><\/tr>
15<\/strong><\/td>Liraglutida<\/td>Decis\u00e3o de desincorpora\u00e7\u00e3o<\/td>P<\/a>ortaria 016\/2026-SES-GO<\/a>
<\/a>(ver DOE-GO, de\u00a019\/03\/2026 – Ed.\u00a024.742 – P\u00e1g. 14)<\/span><\/td><\/tr><\/tbody><\/table>\t\t\t\t\t\t\t\t<\/div>\n\t\t\n<\/div>\n\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":"

Essa \u00e9 a lista de medicamentos e produtos de Cannabis que constam na RECOME e seus respectivos Protocolos Cl\u00ednicos e Diretrizes Terap\u00eauticas (PCDT’s):\u00a0 ORDEM DENOMINA\u00c7\u00c3O USOS APROVADOS E SEUS RESPECTIVOS PROTOCOLOS CL\u00cdNICOS ESTADUAIS PORTARIAS 01 Aflibercepte Edema macular secund\u00e1rio \u00e0 retinopatia diab\u00e9ticaEdema macular secund\u00e1rio \u00e0 oclus\u00e3o venosa da retinaDegenera\u00e7\u00e3o macular relacionada \u00e0 idade forma neovascular […]<\/p>\n","protected":false},"author":584,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":"","_links_to":"","_links_to_target":""},"class_list":["post-204780","page","type-page","status-publish","hentry"],"rttpg_featured_image_url":null,"rttpg_author":{"display_name":"angelicaabadia","author_link":"https:\/\/goias.gov.br\/escoladesaude\/author\/angelicaabadia\/"},"rttpg_comment":0,"rttpg_category":null,"rttpg_excerpt":"Essa \u00e9 a lista de medicamentos e produtos de Cannabis que constam na RECOME e seus respectivos Protocolos Cl\u00ednicos e Diretrizes Terap\u00eauticas (PCDT’s):\u00a0 ORDEM DENOMINA\u00c7\u00c3O USOS APROVADOS E SEUS RESPECTIVOS PROTOCOLOS CL\u00cdNICOS ESTADUAIS PORTARIAS 01 Aflibercepte Edema macular secund\u00e1rio \u00e0 retinopatia diab\u00e9ticaEdema macular secund\u00e1rio \u00e0 oclus\u00e3o venosa da retinaDegenera\u00e7\u00e3o macular relacionada \u00e0 idade forma neovascular…","_links":{"self":[{"href":"https:\/\/goias.gov.br\/escoladesaude\/wp-json\/wp\/v2\/pages\/204780","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/goias.gov.br\/escoladesaude\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/goias.gov.br\/escoladesaude\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/goias.gov.br\/escoladesaude\/wp-json\/wp\/v2\/users\/584"}],"replies":[{"embeddable":true,"href":"https:\/\/goias.gov.br\/escoladesaude\/wp-json\/wp\/v2\/comments?post=204780"}],"version-history":[{"count":2,"href":"https:\/\/goias.gov.br\/escoladesaude\/wp-json\/wp\/v2\/pages\/204780\/revisions"}],"predecessor-version":[{"id":204792,"href":"https:\/\/goias.gov.br\/escoladesaude\/wp-json\/wp\/v2\/pages\/204780\/revisions\/204792"}],"wp:attachment":[{"href":"https:\/\/goias.gov.br\/escoladesaude\/wp-json\/wp\/v2\/media?parent=204780"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}